MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine
17.4.2025 16:36:00 EEST | Business Wire | Press release
MultiSafepay (MSP), an Amsterdam-based payment service provider, which became part of Ant International’s Antom, reported strong growth since its strategic integration with Antom, supporting thousands more SMEs in Europe to scale through innovative solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417858076/en/
Ant International’s new office in Amsterdam City Centre will house MultiSafepay’s operations and enable further collaboration between its business pillars.
Since announcing its acquisition in July 2024, MSP has expanded its merchant base across Europe to 20,000+, an 11% increase. Transaction volumes surged by 44% year-on-year, reflecting customers' robust business growth as well as the addition of new top industry performers. Merchants are increasingly moving to unified payment services, in-person payments are now already at 8% of total volume processed across retail and food & beverage verticals - demonstrating the value of increased efficiency in operations and the benefits of enhancing customer touchpoints.
This acceleration displays the potential of Antom’s post-acquisition strategy to combine local expertise with a global technology suite, benefiting the merchants MSP serves with innovative digital technologies.
MSP provides merchants with unified payment capabilities, supporting more than 40 local and international payment methods, including cards, e-wallets, Buy Now Pay Later, internet banking, across in-person and online channels.
Since becoming wholly-owned subsidiary of Ant International, MSP has been integrating with Antom to help businesses improve operations, and scale with confidence, using the powerful solutions relied on by industry leaders globally. MSP will also look to work with other businesses of Ant International such as WorldFirst to offer inclusive financial services to its SME merchant base.
In under a year, the integration has propelled innovation for merchant expansion, improvements in payment success rates, and infrastructure upgrades, demonstrating the power of combining MSP’s 25-years of expertise with Antom’s global experience.
MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. Supporting a range of technology gives merchants a flexible, cost-effective way to handle payments and demonstrates MSP’s dedication to helping small businesses thrive by offering a solution that fits their unique needs.
Olaf Geurs, CEO of MultiSafepay, commented: “We expect to exceed our 2025 growth projections given current strong numbers and deepened partnership with Ant International. The data shows how SME partners are embracing our joint innovative solutions with Antom to accelerate their digital operations. MultiSafepay's momentum underscores the value of our collaboration in empowering businesses to succeed in today's fast-evolving world.”
“Accelerating the adoption of new technologies like AI in merchant payment services enable us to raise efficiency while maximizing our expertise in the SME sector,” said Gary Liu, General Manager of Antom, Ant International. “By building on MultiSafepay’s platform and Antom’s global expertise, we’re making simple, flexible payments accessible to every business - no matter their size or ambition.”
The company has recently moved to Ant International’s new office in Amsterdam’s vibrant City Centre, enabling collaborations with other Ant International business pillars to directly benefit SMEs.
About Antom
Ant International's Antom is the leading payment and digitisation services provider for merchants around the world. It offers unified merchant payment solutions to serve businesses of all sizes. Antom supports merchants in over 50 countries and regions, enabling them to connect with consumers in more than 200 markets, with the flexibility to accept payments in more than 100 currencies. Beyond payments, it provides digital marketing solutions and merchant digitisation services to help merchant streamline operations and enhance customer engagement.
To learn more, please visit https://www.antom.com/.
About MultiSafepay
MultiSafepay is a leading Amsterdam-based payment service provider, combining decades of expertise with powerful in-house technology to help every business grow faster and compete with confidence, no matter their size or ambition.
By leveling the playing field in payments, we offer European businesses a simple, flexible solution for online, in-person, and unified payments, all through a single platform and integration. With a personal approach to payments, we optimize success rates, reduce complexity, and help your business do more, and earn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250417858076/en/
Contacts
Joshua Way, Ant International
Joshua.way@antgroup.com
Michiel van Werkhoven, MultiSafepay
michiel.vanwerkhoven@multisafepay.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom